PharmaLex Group strengthens the US presence with acquisition of Safis Solutions, The Degge Group, Ltd. and Complya Consulting Group.
The mergers demonstrate PharmaLex’s commitment to the US market and complements its existing EU medical device expertise.
Munich/Frankfurt: As of June 2017, the PharmaLex Group, a leading specialist provider of development consulting and scientific affairs, regulatory affairs and pharmacovigilance and a portfolio company of the funds advised by AUCTUS, has completed the formal acquisitions of Safis Solutions, The Degge Group, Ltd. and Complya Consulting Group.
Safis Solutions is headquartered in Indianapolis, IN, USA. Founded in 2002, the company specializes in regulatory affairs, having a particular strength in medical devices. “The provision of this additional regulatory experience will help support making us a partner of choice for global medical device and combination product projects”, explained Dr. Thomas Dobmeyer, CEO PharmaLex.
The Degge Group’s focuses on pharmacoepidemiology and pharmacovigilance services and was founded in 1988 by Judith K. Jones, MD, PhD, FISPE. In the present era of large-scale global investigations and safety issues. The Degge Group enhances the PharmaLex Group’s offerings with its pharmacoepidemiology expertise and its specialized staff. “The addition of The Degge Group further establishes our intentions to build our US presence following our recent acquisition of Safis Solutions” explained Dr. Tilo Netzer, CEO PharmaLex.
Complya was founded in 2007 by Jonathan Morse and is based in Boston, MA, USA. Their main area of expertise is US FDA GXP Quality Assurance services. The merger enables PharmaLex to build on its existing US FDA Quality and Compliance expertise. “By joining the PharmaLex Group, Complya is now even better positioned to serve clients in new markets and locations, and to provide valuable new services to our existing clients in Boston and internationally” said Jonathan Morse, CEO, Complya Consulting.
The acquisitions strengthen the US footprint of PharmaLex and is the basis to build the new business unit quality & compliance services as well as enables PharmaLex to even better serve its client base globally. The PharmaLex Group now has 100 employees with in total five offices in the US and 25 offices in 12 countries with over 620 employees and more than 650 satisfied clients worldwide.
“Leveraging on the three US acquisitions PharmaLex has now become a truly global player well positioned to serve global customers,” explains Dr. Nicolas Himmelmann, partner at AUCTUS.
The transactions were led by Dr. Nicolas Himmelmann, Benjamin Seifert and Peer Weder.
PharmaLex
PharmaLex combines local expertise with global reach in the area of development consulting and scientific services, regulatory affairs and pharmacovigilance. A proven track record of success in outsourcing programs, more than 25,000 successfully completed projects for over 650 clients worldwide, as well as extensive experience in all therapeutic areas and product groups, including advanced therapy medicinal products and biopharmaceuticals, medical and borderline products and alternative therapeutic approaches.
Contact:
Ms. Eva Keck
Director Marketing, PharmaLexGmbH
eva.keck@pharmalex.com
+49 621 18 15 38 158
Harrlachweg 6; 68163 Mannheim, Germany
AUCTUS Capital Partners AG
With more than 100 transactions since 2001, AUCTUS is the leading private equity firm for the German-speaking SME sector (“Mittelstand“). For its performance, AUCTUS has repeatedly received awards as the best German private equity fund. The AUCTUS team consists of 14 experienced private equity experts and supervises 18 platform enterprises from various industries. AUCTUS seeks majority interests of companies in the context of buy-and-build strategies, succession and corporate spin-offs and provides growth capital to enterprises. The latin word “AUCTUS” translates the entrepreneurial mind-set of focusing on “sustainable growth”. Together with the management teams, AUCTUS strives to increase the value of the portfolio companies by sales and earnings growth. With assets under management of more than EUR 500m, AUCTUS builds on a loyal investor base of renowned financial institutions, successful entrepreneurs and family offices.
Contact:
AUCTUS Capital Partners AG
T +49 (0) 89 15 90 700-25
Email: publicrelations@auctus.com
www.auctus.com
AUCTUS Capital Partners AG
T +49 (0) 89 15 90 700-25
Email: publicrelations@auctus.com
www.auctus.com
